Orbimed Advisors LLC Has $21.53 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Orbimed Advisors LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 300.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,285,400 shares of the biopharmaceutical company's stock after buying an additional 1,715,100 shares during the period. Orbimed Advisors LLC owned about 0.76% of Amicus Therapeutics worth $21,528,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of FOLD. Millennium Management LLC lifted its stake in Amicus Therapeutics by 10.8% in the 4th quarter. Millennium Management LLC now owns 457,014 shares of the biopharmaceutical company's stock valued at $4,305,000 after purchasing an additional 44,449 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Amicus Therapeutics by 10.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 258,149 shares of the biopharmaceutical company's stock valued at $2,432,000 after purchasing an additional 24,316 shares during the last quarter. Hudson Bay Capital Management LP lifted its stake in Amicus Therapeutics by 26.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,804,800 shares of the biopharmaceutical company's stock valued at $17,001,000 after purchasing an additional 379,800 shares during the last quarter. Deutsche Bank AG lifted its stake in Amicus Therapeutics by 11.9% in the 4th quarter. Deutsche Bank AG now owns 822,108 shares of the biopharmaceutical company's stock valued at $7,744,000 after purchasing an additional 87,491 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in Amicus Therapeutics by 132.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,560,410 shares of the biopharmaceutical company's stock valued at $14,699,000 after purchasing an additional 889,968 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on FOLD shares. UBS Group raised their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group cut their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Finally, Wells Fargo & Company cut their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD traded up $0.48 during midday trading on Friday, reaching $6.43. 8,141,440 shares of the company were exchanged, compared to its average volume of 2,809,213. The stock's 50-day moving average price is $7.37 and its 200-day moving average price is $8.92. The stock has a market cap of $1.98 billion, a P/E ratio of -35.72, a PEG ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a one year low of $5.81 and a one year high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.